How should C‑peptide be measured in a patient?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: May 21, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

How to Check for C-Peptide

Measure C-peptide in the fasting state when the simultaneous fasting plasma glucose is ≤220 mg/dL (12.5 mmol/L), or use a random non-fasting sample with concurrent glucose measurement when the patient is seen in clinic. 1

Practical Testing Approaches

For Diabetes Classification (Type 1 vs Type 2)

Fasting C-peptide is the preferred method when you need to distinguish between diabetes types in ambiguous cases 1. The 2023 ADA/EASD guidelines provide clear direction:

  • Only test C-peptide in insulin-treated patients 2, 3
  • Ensure fasting plasma glucose is ≤220 mg/dL (12.5 mmol/L) at time of testing 1
  • Do not test within 2 weeks of a hyperglycemic emergency (DKA/HHS) 2, 3
  • Must measure C-peptide before insulin discontinuation to exclude severe insulin deficiency 2, 3

Interpretation thresholds:

  • <200 pmol/L (<0.6 ng/mL): Severe insulin deficiency, consistent with type 1 diabetes 2, 3
  • 200-600 pmol/L (0.6-1.8 ng/mL): Indeterminate, usually type 1 or MODY, but can occur in insulin-treated type 2 diabetes 2, 3
  • >600 pmol/L (>1.8 ng/mL): Consistent with type 2 diabetes 2, 3

Alternative: Random Non-Fasting C-Peptide

A random non-fasting blood sample is highly practical and clinically valid 4. This approach allows testing when the patient presents to clinic without special preparation:

  • Collect random C-peptide with concurrent glucose measurement 2, 3
  • If concurrent glucose is <4 mmol/L (<70 mg/dL) or patient may have been fasting, repeat the test 2, 3
  • If result is >600 pmol/L (>1.8 ng/mL), the circumstances of testing don't matter 2, 3
  • Very low levels (<80 pmol/L [<0.24 ng/mL]) don't need repeating 2, 3

The random sample within 5 hours of eating can replace formal stimulation testing for classification purposes 2, 3. Research shows random C-peptide correlates strongly with stimulated values (r=0.91-0.96) and maintains excellent sensitivity (100%) and specificity (93%) for detecting severe insulin deficiency 4.

For Hypoglycemia Investigation

C-peptide measurement is essential when investigating non-diabetic hypoglycemia, particularly to rule out surreptitious insulin administration 1, 5.

During documented hypoglycemia (glucose ≤45 mg/dL [2.5 mmol/L]):

  • Measure C-peptide simultaneously with glucose, insulin, and proinsulin 6
  • C-peptide >0.6 ng/mL (>200 pmol/L) indicates inappropriate insulin secretion with nearly 100% sensitivity and specificity 6
  • Also measure beta-hydroxybutyrate and screen for sulfonylureas 7

Critical caveat: These thresholds are not valid in renal insufficiency 6. In kidney disease, use plasma beta-hydroxybutyrate assay and glucagon stimulation test instead 6.

Glucagon Stimulation Test

When formal stimulation is needed (e.g., equivocal results, research protocols):

  • Administer 1 mg glucagon intravenously 7
  • Measure C-peptide at baseline and post-stimulation 1
  • This test balances sensitivity with practicality 8

Urine C-Peptide Alternative

Urine C-peptide creatinine ratio (UCPCR) is a non-invasive alternative 9, 4:

  • Collect single post-stimulated urine sample 9
  • UCPCR <0.2 nmol/mmol has 83% sensitivity and 93% specificity for severe insulin deficiency 4
  • Stable for 3 days at room temperature when collected in boric acid 9
  • Well-correlated with serum C-peptide (r=0.82) 4

Important Clinical Pitfalls

Assay variability is a major limitation. Despite traceability to international standards, different C-peptide immunoassays show significant discrepancies—up to 36.6% mean bias between some platforms 10. This means:

  • Results near decision thresholds require careful interpretation
  • Longitudinal monitoring should use the same assay platform
  • The lack of full standardization implementation affects clinical diagnosis 11, 10

When NOT to measure C-peptide:

  • Routine screening in type 2 diabetes or cardiovascular risk assessment 1
  • Polycystic ovary syndrome evaluation 1
  • Within 2 weeks of ketoacidosis 2, 3
  • When clinical presentation and treatment response clearly define diabetes type 1

Special populations requiring caution:

  • Renal insufficiency (use alternative methods) 6
  • Hepatic insufficiency (thresholds not validated) 6
  • Post-pancreatectomy (thresholds not validated) 6
  • Certain genetic forms of nesidioblastosis (may show atypical patterns) 6

References

Research

Random non-fasting C-peptide: bringing robust assessment of endogenous insulin secretion to the clinic.

Diabetic medicine : a journal of the British Diabetic Association, 2016

Guideline

neuroendocrine tumors.

Journal of the National Comprehensive Cancer Network : JNCCN, 2012

Guideline

fast test: clinical practice and interpretation.

Annales d'endocrinologie, 2013

Research

A Practical Review of C-Peptide Testing in Diabetes.

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2017

Research

Detection of C-Peptide in Urine as a Measure of Ongoing Beta Cell Function.

Methods in molecular biology (Clifton, N.J.), 2016

Research

Comparability of C-Peptide Measurements - Current Status and Clinical Relevance.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2023

Research

Call for Standardization of C-Peptide Measurement.

Journal of diabetes science and technology, 2025

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.